30
Participants
Start Date
August 31, 2002
Primary Completion Date
November 30, 2005
Study Completion Date
April 30, 2010
thalidomide
oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
adjuvant therapy
Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER